Polypeptides-Drug Conjugates for Anticancer Therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202001974
Abstract: Polypeptides are an important class of biodegradable polymers that have been widely used in drug delivery field. Owing to the controllable synthesis and robust side chain-functionalization ability, polypeptides have long been ideal candidates for conjugation… read more here.
Keywords: drug conjugates; conjugates anticancer; polypeptides drug; drug ... See more keywords
Antibody drug conjugates for the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26750
Abstract: The treatment landscape of multiple myeloma (MM) has evolved substantially, but it remains largely incurable so new treatment options are required. Antibody drug conjugates (ADCs) are an emerging therapeutic class used in Cancer to deliver… read more here.
Keywords: drug conjugates; treatment; multiple myeloma; antibody drug ... See more keywords
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Communications"
DOI: 10.1002/cac2.12387
Abstract: Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs approved for the treatment of human epidermal growth factor receptor… read more here.
Keywords: drug conjugates; breast cancer; resistance; antibody drug ... See more keywords
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34507
Abstract: Antibody–drug conjugates (ADCs) have complex molecular structures and have been tested in numerous clinical trials. Therefore, understanding the mechanisms of their toxicity when applied in medical practice is of high importance. read more here.
Keywords: clinical trials; drug conjugates; related adverse; treatment related ... See more keywords
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2278
Abstract: Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of oncology drug development and hold significant promise. There are currently nine ADCs… read more here.
Keywords: drug conjugates; drug; food drug; antibody drug ... See more keywords
Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS
Sign Up to like & getrecommendations! Published in 2022 at "Electrophoresis"
DOI: 10.1002/elps.202200140
Abstract: Antibody–drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their… read more here.
Keywords: drug conjugates; drug; antibody drug; conjugational heterogeneity ... See more keywords
Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.27419
Abstract: Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody–drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers,… read more here.
Keywords: drug conjugates; drug; conjugates adcs; cancer ... See more keywords
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1720
Abstract: Antibody‐drug conjugates are important molecular entities in the treatment of cancer, with 8 antibody‐drug conjugates approved by the US Food and Drug Administration since 2000 and many more in early‐ and late‐stage clinical development. These… read more here.
Keywords: drug conjugates; drug; pharmacology; antibody drug ... See more keywords
Evaluation of hydrophobic‐interaction chromatography resins for purification of antibody‐drug conjugates using a mimetic model with adjustable hydrophobicity
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Separation Science"
DOI: 10.1002/jssc.201900895
Abstract: Abstract Antibody drug conjugates are cytotoxic pharmaceuticals, designed to destroy malignant cells. A cytotoxic molecule is attached to an antibody that binds specific to a cancer‐cell surface. Given the high toxicity of the drugs, strict… read more here.
Keywords: drug conjugates; hydrophobic interaction; antibody; antibody drug ... See more keywords
Bio-Responsive Macromolecular Drug and Small-Molecular Drug Conjugates: Nanoparticulate Prodrugs for Tumor Microenvironment Heterogeneity Management and Therapeutic Response Enhancement.
Sign Up to like & getrecommendations! Published in 2023 at "Small"
DOI: 10.1002/smll.202301656
Abstract: How to break through the poor response of current drug therapy, which often resulted from tumor microenvironment heterogeneity (TMH), remains an enormous challenge in the treatment of critical diseases. In this work, a practical solution… read more here.
Keywords: nanoparticulate prodrugs; drug conjugates; tumor microenvironment; small molecular ... See more keywords
Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0558-1
Abstract: Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs. These drugs consist of a cytotoxic agent connected by a… read more here.
Keywords: hematological malignancies; antibody drug; drug conjugates; treatment hematological ... See more keywords